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Figure 2. Fellows working in Pediatric BMT centres across India.
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Introduction: In 2005, India had less than 10 bone marrow
transplant (BMT) centres, mostly adult BMT programs per-
forming 300 BMT/year. There was a need to train more doctors
in pediatric BMT and set up more BMT centres focussing on
pediatric BMT. Here we describe how capacity for pediatric
BMT was increased in India.
Methods: Initially send doctors to train abroad and then start
a local training program with these initial mentors. Keep
mentoring fellows passing out and help them go abroad to
train further in pediatric BMT. Encourage them to return to
home country & set up new BMT programs, become mentors
themselves & start training young fellows and keep the cycle
going.
Results: Over the course of 13 years (2005 to 2018) initial 2
mentors have trained further 68 fellows of whom 12 are still
in training. A total of 28 went abroad for further training
(Fig 1). Of them 17 have returned to home country and 11
are still in training abroad. Five joined 3-year doctorate of
medicine (DM) program in pediatric hemato-oncology to
train further. The remaining 25 opted to train no further and
join practice. More than half of the fellows; 36 are active
BMT consultants and have helped set up 22 pediatric BMT
programs across 9 states (Fig 2).Of these 22 centres, 4 have
been accredited for fellowship of National Boards (6 stu-
dents/year). Indian Academy of Pediatrics fellowship has
also started in these centres (6 students/year).One centre
has started a DM program (2 students/year). This group col-
laborated to analyse outcome data of pediatric BMT from 8
centres across India and reported overall survival of 70% for
717 children at EBMT 2018 meeting. As per Indian stem cell
transplant registry report 2018, overall BMT centres have
increased to 77 from just 10 in 2005 and annual BMT have
increased in India to 2000/year. Among the allogeneic BMT
>50% are pediatric. In last 5 years (2012 to 2017), 3329 pedi-
atric BMT have been performed in India (autologous-434 &
allogenic-2895 including 636 haploidentical and 348
matched unrelated donor BMT).
Conclusion: In last decade, with mentorship, training & inter-
national collaboration, capacity to do pediatric BMT in India
has improved substantially.Figure 1. International training of fellows.474
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Introduction: The relationship between socioeconomic status
(SES) and HSCT outcomes has not been well described in devel-
oping countries. Our center has established an outpatient-
based HSCT program to reduce costs and improve its access to
patients with different socioeconomic backgrounds. Neverthe-
less, post-HSCT follow-up implies an economic spending that
many patients are unable to afford and may have a clinical
impact.
Objective: We aimed to study the relationship between SES in
transplant patients and clinical outcomes.
Methods: From August 2017 to May 2018, adult patients who
received an HSCT and continued follow-up in our unit were
recruited. They were enrolled into one of two cohorts: Cohort A
included patients who received their first HSCT from January
2007 to July 2017, and Cohort B included those who were trans-
planted from August 2017 to May 2018. A validated question-
naire was applied to determine patients’ SES and demographic
features. Clinical data were also obtained. Study endpoints
included appearance of infections, mucositis, and hospitalizations
by day 100. In patients with allo-HSCT, the cumulative incidence
(CI) of acute GVHD (aGVHD) by day 100, and one-year CI of
chronic GVHD (cGVHD) were assessed. In patients from Cohort
B, one-year overall survival (OS) and disease-free survival (DFS)
were analyzed by Kaplan-Meier method.
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cohort B. Thirty-seven patients received auto-HSCT (44.6%), 22
HLA-identical allo-HSCT (26.5%), and 24 HLA-haploidentical allo-
HSCT (28.9%). Most common diagnosis were lymphoma, acute
leukemia, and myeloma (30.1, 25.3 and 21.7%, respectively).
Median follow-up was 9 months (1-107). Patients were divided
into 3 groups according to SES. Excluding CMV status, there
were no significant differences in pre-transplant features (Fig 1).
We compared outcomes according to SES. We found more
infectious episodes and hospitalization requirements by day
100 in patients with low-SES (70.8 and 62.5%, respectively),
whereas incidence of mucositis was greater in patients with
high-SES (58.3%); p>0.05. In patients receiving allo-HSCT, CI of
aGVHD was higher in those with high-SES (33.3%), while
patients with low-SES had a superior one-year CI of cGVHD;
p>0.05 (Fig 2). One-year OS and DFS in patients from Cohort B
were 93.5 and 74.1%, respectively. There was a trend to find a
decreased one-year OS and DFS in subjects with low-SESFigure 1. Socioeconomic and clinical characteristics of 83 patients undergoing
HSCT.
Figure 2. Cumulative incidence of chronic GVHD in 46 patients receiving allo-
geneic HSCT.compared to those with middle and high-SES (90 and 62.5% vs
94.1 and 77.8% vs 100 and 100%, respectively); p>0.05.
Conclusion: Outcomes after HSCT can be favorable even in low
resource settings. There was a trend to find HSCT-related com-
plications more frequently in patients with low-SES, including
infections, cGVHD and reduced DFS. Special attention should
be given to patients with limited socioeconomic conditions
and adequate compliance must be emphasized to achieve
satisfactory outcomes.475
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Introduction: Contrary to conventional wisdom, the obesity
epidemic is not restricted to industrialized societies. over
115 million people suffer from obesity-related problems in
developing countries.(1)
The traditional view of adipose tissue as a passive storage
depot of excess energy has been challenged. Adipose tissue is a
highly active endocrine organ with the capacity to synthesize
and secrete a variety of adipokines creating a chronic inflam-
matory state. (2)
We tested whether pre-transplant BMI can affect transplant
outcomes in a homogeneous population of patients underwent
HLA-identical sibling transplant with PBSCT graft.
Objectives: To investigate the impact of Pre-transplant BMI on
HSCT outcome.
Methods: Adult patients who underwent Allo HSCT (2000-
2014) at Nasser Institute for Research and Treatment, Cairo,
Egypt, were included.
Patients received their 1st allo HSCT from 6/6 HLA-matched
sibling donors using PBSC graft for treatment of SAA, MDS,
AML, ALL or CML.
Patients aged>50 years and those who received syngeneic trans-
plant were excluded. The final data set included 971 patients.
Patients were classified according to pre-transplant BMI into
five groups following WHO 2007 BMI classification system:
underweight BMI < 18.5, average weight BMI 18.5 to < 25,
over weight BMI 25 to < 30, obese class I BMI 30 to < 35, and
obese class II and III BMI 35 (combined into one group for
analysis).
HSCT outcome was assessed with the following parameters:
time to engraft, development of acute GVHD, development of
chronic extensive GVHD, relapse, non-relapse mortality and
overall survival. Each outcome was adjusted for other statisti-
cally significant variables.
Cox regression models were used to evaluate the impact of
BMI on overall mortality, NRM, relapse, and cGVHD. Logistic
regression was used to evaluate the relationship between BMI
and AGVHD.
Results: Our results showed that obesity class II and III was
associated with increased risk of developing chronic extensive
GVHD (HR=1.98, 95% CI 1.12-3.53, P value 0.02), lower OS
(HR=1.51, 95% CI 1.04-2.20, p=0.03) and higher non-relapse
